Altered levels of salivary and plasma pain related markers in temporomandibular disorders

  • PDF / 1,074,388 Bytes
  • 10 Pages / 595.276 x 790.866 pts Page_size
  • 28 Downloads / 117 Views

DOWNLOAD

REPORT


(2020) 21:105

The Journal of Headache and Pain

RESEARCH ARTICLE

Open Access

Altered levels of salivary and plasma pain related markers in temporomandibular disorders Hajer Jasim1* , Bijar Ghafouri2, Björn Gerdle2, Britt Hedenberg-Magnusson1,3 and Malin Ernberg1

Abstract Background: Different pain syndromes may be characterized by different profiles of mediators reflecting pathophysiological differences, and these alterations may be measured in a simple saliva sample. The aims of the current study were to compare concentration of glutamate, serotonin (5-HT), nerve growth factor (NGF), brainderived neurotrophic factor (BDNF), and substance P (SP) in saliva and plasma from a well-defined group of patients with chronic temporomandibular disorders myalgia (TMD-myalgia) with a group of pain-free controls, and further investigate the relationship between these markers and clinical characteristics. Methods: Patients diagnosed according to the diagnostic criteria for TMD (n = 39), and matched healthy pain-free controls (n = 39) were included. Stimulated whole saliva and plasma samples were collected in the morning. Glutamate was analysed using a colorimetric assay, and 5-HT and SP were analysed by commercially available ELISA. Levels of NGF and BDNF were determined using multiplex electrochemiluminescence assay panel. Results: Patients expressed higher salivary and plasma levels of glutamate (saliva: 40.22 ± 13.23 μmol/L; plasma: 30.31 ± 18.73 μmol/L) than controls (saliva: 33.24 ± 11.27 μmol/L; plasma: 20.41 ± 15.96 μmol/L) (p < 0.05). Salivary NGF (0.319 ± 0.261 pg/ml) and BDNF (3.57 ± 1.47 pg/ml) were lower in patients compared to controls (NGF: 0.528 ± 0.477 pg/ml; BDNF 4.62 ± 2.51 pg/ml)(p’s < 0.05). Contrary, plasma BDNF, was higher in patients (263.33 ± 245.13 pg/ml) than controls (151.81 ± 125.90 pg/ml) (p < 0.05). 5-HT was undetectable in saliva. Neither plasma 5-HT, nor SP levels differed between groups. BDNF and NGF concentrations correlated to levels of psychological distress (p < 0.0005). Conclusion: The higher levels of salivary and plasma glutamate in patients with TMD-myalgia compared to controls strengthens its importance in the pathophysiology of TMD-myalgia. However, the lack of correlation to pain levels question its role as a putative biomarker. Patients with TMD-myalgia further had lower levels of salivary NGF and BDNF, but higher plasma BDNF. These results and their correlations to psychological distress warrant further investigations. Keywords: Biomarker; chronic pain; temporomandibular disorders, Saliva, Myalgia, NGF, BDNF, Glutamate, Substance P, 5-HT

* Correspondence: [email protected] 1 Division of Oral Diagnostics & Rehabilitation, Department of Dental Medicine, Section for Orofacial Pain and Jaw function, Karolinska Institutet and Scandinavian Center for Orofacial neuroscience (SCON), BOX 4064, SE141 04 Huddinge, Sweden Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0